Evidence map›Paper›PMID 42226019›Full record

ArticleHead & neck2026

Treatment-Related Adverse Events and Health-Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review.

N D O'Donnell, E C Ward, L R Wishart, R Perera, C Barrett, K A Edmiston, E Mitchell, A Pigott, R Pitt, K Russell and 2 more

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

N D O'DonnellSchool of Health & Rehabilitation Sciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID https://orcid.org/0009-0009-4209-6489
E C WardSchool of Health & Rehabilitation Sciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID https://orcid.org/0000-0002-2680-8978
L R WishartSchool of Health & Rehabilitation Sciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID https://orcid.org/0000-0002-9474-9121
R PereraSchool of Health & Rehabilitation Sciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID https://orcid.org/0009-0008-0672-9704
C BarrettPrincess Alexandra Hospital, Queensland Health, Buranda, Queensland, Australia.ORCID https://orcid.org/0009-0003-6957-2226
K A EdmistonPrincess Alexandra Hospital, Queensland Health, Buranda, Queensland, Australia.ORCID https://orcid.org/0009-0004-6351-5148
E MitchellPrincess Alexandra Hospital, Queensland Health, Buranda, Queensland, Australia.
A PigottSchool of Health & Rehabilitation Sciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID https://orcid.org/0000-0002-6254-0788
R PittCentre for Functioning and Health Research, Metro South Health, Queensland Health, Buranda, Queensland, Australia.ORCID https://orcid.org/0000-0002-8557-696X
K RussellPrincess Alexandra Hospital, Queensland Health, Buranda, Queensland, Australia.
B A ChanSunshine Coast University Hospital, Queensland Health, Birtinya, Queensland, Australia.ORCID https://orcid.org/0000-0002-6492-1197
R LadwaPrincess Alexandra Hospital, Queensland Health, Buranda, Queensland, Australia.ORCID https://orcid.org/0000-0002-4196-0177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSupportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill-defined. Hence, known treatment-related adverse events (TRAEs) and health-related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care services.

methodsScoping review including 98 studies.

resultsModerate-severe TRAEs occurred at < 10% incidence, with most experiencing mild impacts. Dermatologic, endocrine, pulmonary, hepatic, gastrointestinal, and constitutional complaints were reported in > 40% of studies, with most symptoms occurring during treatment. ICI monotherapy had less reported toxicity than multimodality treatments. Adding ICIs to multimodality treatment creates a minimal increase in TRAEs. HRQoL scores were low, with little change during ICI treatment.

conclusionsICIs for HNSCC are generally well tolerated; however, TRAEs are common and may carry long-term functional consequences. Flexible supportive care pathways are needed to assist early detection and individualized management of functional impacts to optimize survivorship.

Indexed as

Head and Neck NeoplasmsImmune Checkpoint InhibitorsQuality of LifeSquamous Cell Carcinoma of Head and NeckFemaleHumansMaleImmune Checkpoint Inhibitorshead and neck cancerimmune checkpoint inhibitorimmunotherapyquality of lifescoping reviewsupportive caresymptoms

Identifiers

PMID42226019
PMCPMC13653308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.